# SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

> **NCT02592421** · PHASE3 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 30 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02592421
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-23
- **Primary completion:** 2018-10-01
- **Final completion:** 2019-10-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02592421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02592421, "SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02592421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*